Novavax Receives the Tech Council of Maryland’s Chairman’s Award

GAITHERSBURG, Md., May 12, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it received the Tech Council of Maryland’s (TCM) Chairman’s Award. The award was announced at the TCM Industry Award Celebration on May 11, 2016. 

The Chairman's Award is presented to a member company or individual that best exemplifies excellence in Maryland's technology or life science industry.  The Award recognizes a company that is a pillar in the community, not only through market success or job creation, but by consistently giving back, getting involved and advancing the climate for innovation.

“Novavax is the embodiment of what we look for when selecting an honoree for the Chairman’s award. The company has built a successful business, employing 450 people in Maryland who are developing vaccines that positively impact global health, and has played an important role in fostering growth of the state’s life sciences community,” said Rene B. LaVigne, TCM chairman-elect and president and CEO of Iron Bow Technologies. "TCM appreciates Novavax’s significant contributions to the association, the state’s economy and innovations in healthcare."

“I am honored to accept this award on behalf of the entire Novavax team,” said Stanley C. Erck, President and CEO, Novavax. “The Tech Council of Maryland facilitates a collaborative community of technology and life science companies who aim to make an impact in our region and beyond. We are thrilled that this award recognizes the hard work and dedication of our more than 450 SuperNovas, our groundbreaking achievements in developing novel vaccines and our commitment to the Maryland life science and technology community.”

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.

Contact:

Novavax, Inc.Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations

[email protected]
240-268-2000

Russo Partners, LLCDavid SchullTodd Davenport, Ph.D.

[email protected][email protected]
212-845-4271